TRVI vs UPB
TRVI: Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated with severe lung diseases like IPF. UPB: Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of severe respiratory inflammatory diseases.
Side-by-side fundamentals
| Metric | TRVI | UPB | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $18.12 | $6.57 | |
| Market cap as of 2026-07-31 | $2.6B | $358M | |
| Net margin as of 2026-07-31 | n/a | -4719.0% | |
| Operating margin as of 2026-07-31 | n/a | -5176.5% | |
| ROE as of 2026-07-31 | -24.5% | -43.8% | TRVI higher |
| ROA as of 2026-07-31 | -23.4% | -42.3% | TRVI higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-31 | n/a | +13.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.5% | |
| Beta as of 2026-07-31 | 1.04 | 1.10 | |
| 1-year return as of 2026-07-27 close | +130.2% | -56.7% | TRVI higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.